<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="115838">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01707368</url>
  </required_header>
  <id_info>
    <org_study_id>DE-Daivobet-longterm-NIS-2012</org_study_id>
    <nct_id>NCT01707368</nct_id>
  </id_info>
  <brief_title>Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation</brief_title>
  <official_title>Course of Psoriasis During Long Term Treatment With Calcipotriol Plus Betamethasone in Gel Formulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to document the course of disease and relapse
      management during treatment with Daivobet® Gel under consideration of patient`s individual
      application habits under daily use conditions.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The course of disease and relapse management during treatment with Daivobet® Gel under consideration of patient`s individual application habits under daily use conditions.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of exacerbations and relapses during one year observation time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physician's global Assessment of psoriasis vulgaris</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment on 6-step scale from &quot;no visible disease (O)&quot; to &quot;very severe disease (5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of participants with serious and non-serious adverse drug reactions, according to organ classes.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>all eligible patients</arm_group_label>
    <description>Daivobet® Gel once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daivobet® Gel</intervention_name>
    <description>Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.</description>
    <arm_group_label>all eligible patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Psoriasis vulgaris visiting their attending dermatologist in the primary
        care clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with light to moderate psoriasis vulgaris of trunk and extremities and
             treatment with Daivobet® Gel was planned anyway.

          -  Minimum of 3 years diagnosed psoriasis vulgaris.

        Exclusion Criteria:

          -  Previous therapy with Daivobet® Gel

          -  Systemic therapy of psoriasis vulgaris

          -  Contraindications of Daivobet® Gel in the German package insert

          -  people that are incapable to give free consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Rosenberg, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>private practise, D- 49078 Osnabrück, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PD Dr. med. Rosenbach</name>
      <address>
        <city>Osnabrück</city>
        <state>Niedersachsen</state>
        <zip>49078</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 22, 2013</lastchanged_date>
  <firstreceived_date>October 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Psoriasis vulgaris</keyword>
  <keyword>Plaque Psoriasis</keyword>
  <keyword>Daivobet® Gel</keyword>
  <keyword>Germany</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
